ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1087

Nonmemory B Cell Signature Alterations in Belimumab Patients

Karina Marianne D. Torralba1, Vaneet Sandhu2, Abigail Benitez1 and Sheila Lezcano3, 1Rheumatology, Loma Linda University, Loma Linda, CA, 2Division of Rheumatology, Loma Linda University, Loma Linda, CA, 3Rheumatology, Loma Linda University Medical Center, Loma Linda, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cell memory, B cell targeting, belimumab and flow cytometry, Lupus

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Insight into B cell subset dynamics and homeostasis can provide a biological rationale for use of B cell targeted therapies in SLE patients. Using our B cell signature (BCS) approach we wanted to assess whether treatment with Belimumab would result in a unique BCS that reflects a reduction in B cell subsets that are most sensitive to B cell activating factor (BAFF) depletion. Our BCS used the CD21/CD24 model that delineates analogous mouse and human nonmemory B cell subsets. Mouse studies have used CD21 and CD24 co-expression to identify which subsets are susceptible to BAFF depletion.

Methods: PBMCs were isolated from healthy donors, and SLE patients on Belimumab or standard of care therapy (SCT). Cells were stained for flow cytometry to identify nonmemory and memory subsets. BCS were determined based on the frequency of each B cell subsets within the nonmemory and memory pools and compared across treatment groups. One-way ANOVA test and Tukey’s post-hoc test were used for statistical analysis.

Results: Our evaluation of BCS showed that Belimumab (n=13) patients had significantly higher proportions of nonmemory transitional 1 cells (p = 0.0062) compared to SCT (n=24) patients and healthy controls (n=14). Alternately, Belimumab patients had significantly lower proportions of nonmemory transitional 2 subset (p=0.0014) compared to healthy controls. FM (naïve) cells displayed no significant differences between the three groups. When we assessed the ratio of T1 to T2, Belimumab B cells had a larger ratio compared to both healthy and SCT (p=0.0033), but healthy and SCT were not significantly different. We also evaluated total transitional B cells to FM cells and noted no significant differences.

Conclusion: Our results show that B cell subsets must be stringently assessed as indicated by the transitional B cell subset data. BCS from Belimumab patients display unique profiles compared to both SCT and healthy donors. Our future studies will consist of a longitudinal evaluation of BCS in pre-Belimumab treatment and at subsequent time points in order to correlate BCS alterations with specific patient clinical characteristics.


Disclosure: K. M. D. Torralba, GlaxoSmithKline, 9,ACR, USSONAR, 9; V. Sandhu, None; A. Benitez, None; S. Lezcano, None.

To cite this abstract in AMA style:

Torralba KMD, Sandhu V, Benitez A, Lezcano S. Nonmemory B Cell Signature Alterations in Belimumab Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/nonmemory-b-cell-signature-alterations-in-belimumab-patients/. Accessed March 3, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nonmemory-b-cell-signature-alterations-in-belimumab-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.